THE US Food and Drug
Administration has expanded the
approved use of Zytiga (abiraterone
acetate) to treat men with latestage
(metastatic) castrationresistant
prostate cancer prior to
receiving chemotherapy.
The FDA initially approved Zytiga
in April 2011 for use in patients
whose prostate cancer progressed
after treatment with docetaxel, a
chemotherapy drug.
Zytiga is a pill that decreases the
production of male sex hormone
testosterone.
In Australia, the drug was
approved in June this year, for use
in combination with prednisone or
prednisolone in patients with
metastatic castrate-resistant
prostate cancer who have received
prior chemotherapy containing a
taxane (PD 12 June).The above article was sent to subscribers in Pharmacy Daily's issue from 12 Dec 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Dec 12
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.